Based on the previous research, we developed a prognostic risk model in combination with the clinical CAPRA score with the normalized expression score of PDE4D7 as well as two other PDE4D long transcripts, namely PDE4D5 and PDE4D9, to predict the post-surgical risk of prostate cancer recurrence in a pre- and post-surgical diagnostic setting [22,23,24]. The gene discussed is PDE4D; the disease is Familial prostate cancer.